



| | | Neo | adjuvant | | |
|----------|---------------|---|---|---|-----------------|
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |
| Parajuli | Stephany Ruiz | UCI 21-185: A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | HER2-targeting antibody drug conjugate | Locally assessed HER2-positive (IHC 3+ or ISH+) T0-4, N1-3, M0 or >T3, N0, M0 | Open to Accrual |
| Yamamoto | Baoan Huynh | UCI 21-106: A Phase II Open-Label, Dose-Finding Study to Determine the Optimal Dose for Lymph Node Visualization Using ASP5354 in Participants with Breast Cancer or Melanoma Undergoing Sentinel Lymph Node Biopsy | Optical imaging agent | Female patients with localized breast cancer (Stage I/II, NOMO) No prior neoadjuvant chemotherapy No prior surgery/radiation to area of LN detection No definitive LN metastasis | Suspended |
| | | Ad | djuvant | | |
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |
| Healy | Stephany Ruiz | CCTG-MA39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer | Regional Radiotherapy | ER+, HER2- Women with newly diagnosed biomarker low risk node positive and T3N0 breast cancer with no evidence of metastases that have been treated by mastectomy or BCS. Oncotype DX recurrence score ≤ 25 | Open to Accrual |
| Parajuli | Stephany Ruiz | A011801: The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib | Antibody drug conjugate + kinase inhibitor | Patients must have HER2+ breast cancer with residual disease after NACT No prior treatment w/ TDM-1 | Open to Accrual |
| Parajuli | Stephany Ruiz | UCI 22-141 A Phase III Open-label, Randomized Study of Datopotamab Deruxtecan (Dato DXd) with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer who have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes Following Neoadjuvant Systemic Therapy and Surgical Resection | PDL-1 inhibitor | TNBC Completed at least 6 cycles of newadjuvant tx containing anthracycline and/or a taxane with or without carboplatin, with or without pembro No adjuvant systemic tx No known germline BRCA1 or BRCA2 mutation | Open to Accrual |
| Mehta | Stephany Ruiz | NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer | radiation therapy versus no radiation therapy + Endocrine therapy | Patients with resected pT1N0M0, HER2-Negative, ER and/or PR-Positive Breast Cancer and Oncotype-DX Recurrence Score ≤ 18 | Open to Accrual |
| | | | etastatic | | I |
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status |
| Parajuli | Alexis Chavez | UCI 22-114: A Phase III, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared with Exemestane Plus Everlimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | Proteasome-mediated degradation | Prior ET with CDK4/6i (metastatic: disease progression >6 months after initiation ET + CDK) (adjuvant: relapse while taking or within 12 months of exposure to combo adjuvant ET and CDK) | Open to Accrual |
| Parajuli | Alexis Chavez | ETCTN 10546: Phase I TNBC Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer | Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA) | Must have histologically confirmed TNBC (ER and PR ≤10%, HER2- negative per ASCO/CAP guidelines) that is metastatic or unresectable. | Open to Accrual |




| Parajuli | Stephany Ruiz | UCI 22-222: A Phase III, Mutlicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant versus Alpelisib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy | PI3K inhibitor | Histologically or cytologically confirmed adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent HR+, HER2- (HER2 immunohistochemistry (IHC) score of 0 or 1+, or HER2 IHC score of 2+) Disease progression after or during treatment with a combination of CDK4/6i and ET (must have received no more than two prior lines of systemic therapy in the locally advanced (recurrent or progressed) or metastatic setting) | Open to Accrual |
|----------|---------------|--|----------------|---|-----------------|
|----------|---------------|--|----------------|---|-----------------|



| Parajuli | TBD | UCI 22-139: A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) | PI3K/mTOR inhibitor | ER+/PR+, Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI) At least 2 weeks beyond treatment with a targeted therapy or major surgery and at least 3 weeks beyond immunotherapy and/or radiation therapy | Open to Accrual |
|----------|---------------|--|--|---|-----------------|
| Mehta | Stephany Ruiz | UCI 19-145 A Phase II, Open-Labeled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer | CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor | Breast cancer with ER+ or PR+Her2 Exclude HER2+ or TNBC, received (neo)adjuvant endocrine or chemotherapy <12 months before. No prior treatment with CDK4/6 inhibitor and/or fulvestrant | Open to Accrual |
| Parajuli | Stephany Ruiz | UCI 21-212: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 | Antibody drug conjugate | Patients with locally advanced inoperable or metastatic TNBC who have not received previous systemic therapy for advanced disease and whose tumors are PD-L1 positive at screening Must have completed treatment for Stage I to III breast cancer, if indicated, and ≥ 6 months must have elapsed between completion of treatment with curative intent | Open to Accrual |
| Parajuli | Alexis Chavez | UCI 22-09: A Phase lb, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors Likely to Express B7-H4 | Antibody drug conjugate | Metastatic TNBC, HR+/HER2- breast cancer, or endometrial cancer, or ovarian, fallopian tube, or primary peritoneal cancer. For HR+/HER2- patients must have received at least one line of systemic therapy which must have included CDK 4/6 inhibitor + endocrine therapy (ET), in an advanced or metastatic setting For TNBC must have received at least 2 lines of systemic therapy in locally advanced or metastatic BC setting. | Open to Accrual |
| Parajuli | Alexis Chavez | ETCTN 10302: Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer | Bone-targeted alpha particle emitting radiopharmaceutical | HER2-, metastatic breast cancer If HR+, disease should have progressed on at least one line of hormone therapy and a CDK 4/6 inhibitor in metastatic setting No prior therapy w/ radionuclides | Open to Accrual |
| Parajuli | Alexis Chavez | ETCTN 10287: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA) | Pan-class I PI3K inhibitor | HR+/HER2- metastatic breast cancer No more than one chemotherapy line in metastatic setting For patients enrolling on Phase 2 portion of the study: - must have resistance to endocrine therapy in metastatic setting -no prior treatment w/ CDK 4/6 inhibitor, Fulvestrant, or PI3K inhibitor in metastatic setting -no brain metastasis | Suspended |
| Parajuli | Alexis Chavez | SWOG S2007: A Phase II Trial of Sacituzumab Govitecan for Patients with HER2- Negative Breast Cancer and Brain Metastases | Antibody drug conjugate | HER2- invasive breast cancer with brain metastasis CNS progression after previous CNS-directed therapy | Open to Accrual |



| Parajuli | Alexis Chavez | UCI 21-57: A Phase Ib/II, 2-Part, Open-Label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination with ALX148 in Advanced HER2-Expressing Cancer | lgG1-like antibody + CD47 inhibitor | Locally advanced or metastatic HER2-positive or HER2-low (IHC1+/IHC2+, HER2-negative) breast cancer. Must have progression during or after the most recent treatment for advanced/metastatic cancer. No prior treatment with anti-CD47 or SIRP-alpha agent. If brain metastasis is present, disease must be stable. For HER2-low subjects, no prior HER2-targeted therapy is allowed. PART 2 DOSE EXPANSION COHORTS: Cohort 1 HER2+; Cohort 2 HER2-LOW | Open to Accrual |
|----------|---------------|---|--|--|-----------------|
| Parajuli | I TRD | UCI 21-82: A Phase I/II, Open Label, Dose-Escalation Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects with Solid Tumors | XBP1-splicing inhibitor | Phase I: Relapsed refractory metastatic breast cancer (TNBC or ER+/HER2-) w/ advanced solid tumors. Must have progressed on at least 2 lines of therapy. Cohort C2A: 300 mg + Abraxane combo Phase II: no more than three lines of systemic therapy in the metastatic setting. Cohort A-TNBC, Cohort B-MYC+, Cohort C-ER+/HER2-, Cohort D-TNBC | Suspended |



| | Solid Tumors/Basket Trials | | | | | |
|-----------|----------------------------|--|---|--|-----------------|--|
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status | |
| Choi | Daniel Na | Alliance A071701: Genetic Testing in Guiding Treatment for Patients with Brain Metastases | CDK inhibitor + PI3K inhibitor + NTRK/ROS1 inhibitor | Histologically confirmed metastatic disease to the brain from any solid tumor. If progression occurred for the following tx in the metastatic setting: for HER2-positive breast cancer received prior HER-2 directed therapy; for TNBC, at least one chemotherapy in metastatic setting | Open to Accrual | |
| Kalebasty | Madina Popal | UCI 20-179: A Phase I/IB First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients with Advanced Solid Tumors | SHP2 inhibitor | Patients must have a metastatic solid tumor with MAPK-pathway alterations (excluding BRAF V600x) and no avaialble SOC therapies Patients with tumors harboring known activating mutations in BRAF V600X or SHP2 will be excluded Patients must not have previously received a SHP2 inhibitor | Open to Accrual | |
| Ou | Richard Chang | UCI 21-12: A Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors | mTOR inhibitor | Advanced solid tumors that have failed, are intolerant to, or are considered ineligible for SOC anticancer treatments No prior mTOR and/or PI3K inhibitors | Open to Accrual | |
| Nagasaka | Jenny Choe | UCI 18-21: A Phase I/II Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) | RET Receptor Tyrosine Kinase inhibitor that harbors RET alterations | Patient with RET fusion-positive solid tumor or an advanced solid tumor that harbors a RET gene alteration (excluding synonymous, frameshift, or nonsense mutation) | Open to Accrual | |
| Valerin | | UCI 20-67: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors | Immunotherapy agent targeting NK cells. | Locally advanced or metastatic solid tumors w/ HER2 expression by immunohistochemistry and/or erbb2 amplification and/or erbb2 activating mutations must be documented on either archival tissue or fresh tumor biopsy. | Open to Accrual | |
| Nagasaka | Celest Ramirez | UCI 21-161: A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors | ROR2 Monoclonal Antibody | Advanced unresectable or metastatic solid tumors that have failed all SoC Therapy. ROR2-positive disease determined by IHC | Open to Accrual | |



| Parajuli | I TRD | UCI 21-82: A Phase I/II, Open Label, Dose-Escalation Study of Oral ORIN1001 With and Without Chemotherapy in the Treatment of Subjects with Solid Tumors | XBP1-splicing inhibitor | Phase I: Males or females with advanced solid tumors for which no effective standard of care treatments are available. Cohort 5: 500 mg Single Agent | Suspended |
|----------|---------------|---|-------------------------|---|-----------------|
| Dayyani | Miranda Duron | UCI 21-146: An Open-Label, Multi-Center, Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Anti-Tumor Activity and Pharmacokinetics of MRG004A in Patients with Tissue Factor Positive Advanced or Metastatic Solid Tumors | Antibody drug conjugate | Stage III or IV locally advanced or metastatic NSCLC, breast cancer, or ovarian cancer, or any stage recurrent disease Must be receiving cancer treatment with carboplatinum-based combination chemotherapy regimens Must have a platelet count < 75 x 109/L | Open to Accrual |



| | Non-Treatment Trials (Diagnostic/Screening/Basic Science) | | | | | | |
|--------------|---|--|-------------------------------|--|--------------------|--|--|
| PI | CRC | Protocol #/Title | Mechanism | Primary In/Ex Criteria | Status | | |
| Parajuli | Billy Sanchez | UCI 17-05: Understanding Intratumoral Heterogeneity Using Single Cell RNA Sequencing | RNAseq | Patients with or without cancer who undergo prophylactic mastectomy, reduction mammoplasty or lumpectomy. Patients (stage I-IV) irrespective of the Hormonal or Her-2 receptor and BRCA status who will undergo breast or axillary node biopsy, definite surgery or prophylactic surgery | Open to Accrual | | |
| Chan | Matthew Heshmatipour | UCI 21-33: Electroacupuncture for the Management of Complex Symptoms in Cancer Patients and Survivors: A Feasibility Study | Electroacupuncture | Patients with Stage I-III solid tumors, except CNS tumors Patients with metastasis, psychiatric or mental disorders, needle phobia, bleeding disorders, or have already received acupuncture treatment in the past 3 months will be excluded. | Open to Accrual | | |
| Anton-Culver | TBD | UCI 16-23: Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM study (Women Informed to Screen Depending on Measures of Risk)] | Risk based screening strategy | Patients must be between the ages of 40 to 74 years old. Patients must agree to receive breast screening at an Athena site (UCSF, UCSD, UCLA, UCI, or Stanford). | Open to Accrual | | |
| Daroui | TBD | UCI 13-19: Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III Breast Cancer | Data Collection | Patients treated with chemotherapy followed by Mastectomy | Open to Accrual | | |
| Parajuli | Alexis Chavez | UCI 18-136: Blood Collection Protocol for the Analysis of Exosomes in Patients with Breast Cancer | Blood Collection | Patient with Stage I, Stage II, Stage III and Stage IV Breast cancer (HR+, HER2+, triple positive or triple negative) | Open to Accrual | | |
| Bristow | TBD | UCI 19-25: Baseline Assessment of Cancer Health Disparities in Underserved Populations in California | Baseline Assessment | Patients must be at least 18 years of age and diagnosed with breast cancer | Pending Activation | | |

Aalvarez 509-6084/Sruiz 509-2698 CColmenares 509-2172/NTharani 509-369 KMueller 509-2369/BHuynh 509-6233 AAguilar 509-2431/CRamirez 509-2738 DNa 509-2759/Achavez 509-2442